Amicus CEO Crowley bags a gene therapy company, a new pipeline — and a great photo op — for $100M in cash
Amicus CEO John Crowley has struck a deal to buy up a portfolio of gene therapies for an extremely rare disease — bagging a small biotech for $100 million in cash plus hundreds of millions in milestones. And it includes some great optics.
Crowley, who’s been fond of highlighting a biotech career inspired by a daughter afflicted with Pompe disease, is acquiring a company launched by Hollywood producer Gordon Gray and his wife, Kristen, whose own daughters suffer from Batten disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
